Medical Advocates
Ethics and Infectious Diseases
  Ethical Challenges
Screening/Testing
 Refusal of Care/Services
Detention
Patient Exploitation
Compulsory Treatment
Decision-Making
Reproduction
Transplants
End-of-Life Care
Enteral Nutrition
Professional Associations
National Challenges         Sterilization
Bioterrorism                     Prison Challenges
 HIV Exceptionalism           Conflicts of Interest
Pharmaceutical Industry   Pregnancy
HIV Prevention   
Stigma
 Physician Reimbursement 
Ethics and Disease Challenges and Duties
 HIV Cure
 Ebola Virus Disease
 Executions






 
Ethics Main Page Main New and Noteworthy Home Page

Medical Advocates
Efavirenz (Sustiva/Strocrin)
 
Journal Citations: Adverse Events

Breast Disorders
 Cardiovascular Disorders
 Cutaneous Disorders
 Hepatic Disorders
 Hypersensitivity
 Metabolic Disorders
 Mental Disorders
 Neurological Disorders
 Pulmonary Disorders
 Renal/Urinary Tract Disorders
 Sleep Disorders
Quality of Life
Efavirenz Main Page Main New/Newsworthy Home Page      
Last Update:  August 16, 2008
 Perinatal Journal Data are in the Perinatal Data Page. Pediatric Journal Data are in the Pediatric Data Page
  Documents identified with this icon are in Portable Document Format (PDF) and require the Adobe Acrobat Reader
Breast Disorders
       
  Efavirenz-associated gynecomastia: report of five cases and review of the literature.
 Jover F, Cuadrado JM, Roig P,et al  
Breast J. 2004 May-Jun;10(3):244-6.
 Abstract 
 
A case-control study of gynecomastia in HIV-1-infected patients receiving HAART
 Rahim S, Ortiz O, Maslow M, Holzman R. 
AIDS Read. 2004 Jan;14(1):23-4, 29-32, 35
 Abstract
 
  FULL-TEXT ARTICLE
Efavirenz-associated breast hypertrophy in HIV-infection patients.
Mercie P, Viallard JF, Thiebaut R, et al.
AIDS 2001 Jan 5;15(1):126-9
Paper
Cardiovascular Disorders
       
  FULL-TEXT ARTICLE
 Nevirapine and Efavirenz Elicit Different Changes in Lipid Profiles in Antiretroviral-
Therapy-Naive Patients Infected with HIV-1
van Leth F, Phanuphak P, Stroes E, et al
PLOS Vol2 Issue 9 Sep 2005
 Paper
Cutaneous Disorders
 
 
Rashes in HIV-infected patients undergoing therapy with nevirapine or efavirenz.
 Hartmann M, Brust J, Schuster D, et al 
Hautarzt. 2005 Feb 23
 Abstract 
 
Incidence and risk factors for rash in Thai patients randomized to regimens with
nevirapine, efavirenz or both drugs.
 Ananworanich J, Moor Z, Siangphoe U, et a;
AIDS. 2005 Jan 28;19(2):185-192
 Abstract 

Efavirenz-induced skin eruption and successful desensitization.
Phillips EJ, Kuriakose B, Knowles SR. 
Ann Pharmacother 2002 Mar;36(3):430-2
Abstract       

 
Hepatic Disorders
 
 
Hepatotoxicity in patients prescribed efavirenz or nevirapine.
 Brück S, Witte S, Brust J,  et al 
Eur J Med Res. 2008 Jul 28;13(7):343-8.
 Abstract   
 
Risk and determinants of developing severe liver toxicity during therapy with
nevirapine-and efavirenz-containing regimens in HIV-infected patients.
 Ena J, Amador C, Benito C, Fenoll V. et al 
Int J STD AIDS. 2003 Nov;14(11):776-81.
Abstract   

Incidence of Liver Injury After Beginning Antiretroviral Therapy with  Efavirenz or
Nevirapine.
Martin-Carbonero L, Nunez M, Gonzalez-Lahoz J, Soriano V
 HIV Clin Trials 2003 Mar-Apr;4(2):115-120
Abstract   

NNRTI hepatotoxicity: efavirenz versus nevirapine.
Pulido F, Torralba M.
J HIV Ther 2002 Nov;7(Suppl 2):S3-S9
 Abstract

Fulminant hepatic failure after the start of an efavirenz-based HAART regimen in a
treatment-naive female AIDS patient without hepatitis virus co-infection.
Abrescia N, D’Abbraccio M, Figoni M, et al.
Antimicrob Chemother 2002 Nov;50(5):763-5
 Abstract

Hepatotoxicity associated with nevirapine or efavirenz-containing antiretroviral therapy:
Role of hepatitis C and B infections.
Sulkowski MS, Thomas DL, Mehta SH, et al.
Hepatology 2002 Jan;35(1):182-9
Abstract

  
Hypersensitivity
 
 
Efavirenz-Induced Hypersensitivity Reaction Manifesting in Rash and Hepatitis in a Latino Male
(March).
 Leung JM, O’Brien JG, Wong HK, Winslow DL.
Ann Pharmacother. 2008 Feb 5
Abstract
 
Association of Efavirenz Hypersusceptibility with Virologic Response in ACTG 368, a Randomized
Trial of Abacavir (ABC) in Combination with Efavirenz (EFV) and Indinavir (IDV) in HIV-Infected Subjects
with Prior Nucleoside Analog Experience.
 Demeter LM, Degruttola V, Lustgarten S, et al
HIV Clin Trials. 2008 Jan-Feb;9(1):11-25
 Abstract
 
Severe efavirenz-induced hypersensitivity syndrome (not-DRESS) with acute renal failure.
 Angel-Moreno-Maroto A, Suarez-Castellano L, Hernandez-Cabrera M, Perez-Arellano JL.
 J Infect. 2005 Jul 1;
 Abstract

Pulmonary hypersensitivity reaction induced by efavirenz.
Behrens GM, Stoll M, Schmidt RE.
 Lancet 2001 May 12;357(9267):1503-4
 Abstract

  
Metabolic Disorders
 
 
A WEEK-IN-REVIEW FEATURED REPORT
Insulin resistance in HIV-infected patients receiving long-term therapy with efavirenz,
lopinavir/ritonavir and atazanavir.
 Bernal E, Masiá M, Padilla S, et al 
Med Clin (Barc). 2007 Jul 14;129(7):252-4.
 Abstract
 
A WEEK-IN-REVIEW FEATURED REPORT
Long-Term Body Fat Outcomes in Antiretroviral-Naive Participants Randomized to Nelfinavir
or Efavirenz or Both Plus Dual Nucleosides: Dual X-Ray Absorptiometry Results From A5005s,
a Substudy of Adult Clinical Trials Group 384.
 Dubé MP, Komarow L, Mulligan K, et al 
J Acquir Immune Defic Syndr. 2007 Jun 21;
 Abstract
 
Body Fat and Other Metabolic Effects of Atazanavir and Efavirenz, Each Administered in Combination
with Zidovudine plus Lamivudine, in Antiretroviral-Naive HIV-Infected Patients.
Jemsek JG, Arathoon E, Arlotti M, et al
Clin Infect Dis. 2006 Jan 15;42(2):273-80.
 Abstract
 
Glucose metabolism, lipid, and body fat changes in antiretroviral-naive subjects randomized to nelfinavir
or efavirenz plus dual nucleosides.
Dube MP, Parker RA, Tebas P, et al
AIDS. 2005 Nov 4;19(16):1807-1818.
Abstract

Long-term metabolic consequences of switching from protease